Clara Biotech hits $850K in seed funding roundup, preparing to launch first product
June 15, 2021 | Startland News Staff
An emerging biotech startup in the region is reporting a busy spring with a significant seed round already raised and key steps under way to launch its product: a solution that removes manufacturing roadblocks for breakthrough drugs.
“We’re in an exciting and growing space and currently have low regulatory hurdles in the research stage,” said Jim West, co-founder of Clara Biotech, a Lawrence-based company already buoyed by its founding team’s expertise in exosome technologies, pharmaceutical development, engineering and building life science companies.
Elevator pitch: Clara Biotech is building an exosome isolation platform that solves a huge roadblock around manufacturing that helps the entire biopharma industry make future breakthrough drugs that may not otherwise get approved. We founded Clara Biotech to help move exosomes from research to patient.
Jim West, Clara Biotech
“We’re looking for smart money investors who can help us develop our market position, scale the technology and become the platform that companies can use to get exosome therapies to the patients who need them most,” he continued, detailing Clara Biotech’s momentum in a company snapshot update.
Off the heels of announcing an undisclosed investment by Kansas City-based Fountain Innovation Fund, the startup has raised $850,000 for its seed round, West said, with additional investments from angel investors in Boston, San Francisco, India and Kansas City.
Dr. Mei He, Clara Biotech
Clara Biotech recently received a tranche of angel tax credits, still available to qualified investors, he added.
The seed round is expected to help the company debut its beta ExoRelease exosome isolation kit, as well as continue to scale, West said.
Click here to read Clara Biotech’s full snapshot update.
“We are generating revenue and launching our first product,” he said. “At a recent conference for exosome therapeutics, sample preparation quality was the major limiting factor in manufacturing and receiving FDA approval. Our groundbreaking solution resulted in a 70 percent lead conversion rate of all companies attending (which includes investment groups and competitors). We’re currently working with and growing a number of paying early customers including some major pharmaceutical players.”
Founded in 2018 at the Bioscience and Technology Business Center in Lawrence, Clara Biotech’s therapeutic applications range from personalized medicine, targeted drug delivery, immunotherapy, and orphan and rare diseases. It’s solutions are focused on early cancer detection, Alzheimer’s disease, and virus detection.
Click here to learn more about Clara Biotech and how its technology works.
This story is possible thanks to support from the Ewing Marion Kauffman Foundation, a private, nonpartisan foundation that seeks to build inclusive prosperity through a prepared workforce and entrepreneur-focused economic development. The Foundation works to change conditions, address root causes, and break down systemic barriers so that all people – regardless of race, gender, or geography – have the opportunity to achieve economic stability, mobility, and prosperity.
For more information, visit www.kauffman.org and connect with us at www.twitter.com/kauffmanfdn and www.facebook.com/kauffmanfdn.
2021 Startups to Watch
stats here
Related Posts on Startland News
Study with USDA researchers affirms startup’s AI-powered facial recognition for cows can detect sick animals
A collaborative study between an Overland Park animal agtech startup and the U.S. Department of Agriculture successfully corroborated MyAnIML’s predictive ability to proactively manage devastating disease outbreaks in cattle production, the company announced this week. MyAnIML uses first-of-its-kind, proprietary facial recognition and deep learning technology to analyze cow muzzles — accurately predicting Infectious Bovine Keratoconjunctivitis…
KC startup’s bone cancer treatment for dogs earns ‘milestone’ USDA validation
A decade of hard work by a veteran entrepreneur and her Olathe-based team has cleared a significant hurdle on the pathway to licensure as its first-in-class adoptive cell therapy for dog cancer gains a critical nod of approval from federal regulators. ELIAS Animal Health, a leading companion animal cancer therapeutics company, recently announced that the…
Meet customers where they are (and they’re on TikTok): Marketing experts urge startups to invest in brand building
Like it or not, “TikTok remains king,” said Mikita Burton, encouraging startup founders to balance negative headlines about the video-sharing social media platform with its incredible potential for reaching their most-sought-after audiences. “We don’t just get to pick our customers’ favorite platforms, so you need to be where they are,” Burton, a social media strategist…
Bo Lings owners adapt to lifestyle trends with new fast casual concept in River Market
A new City Market dining option from the couple behind the Bo Lings restaurant chain is serving up fast casual Chinese dishes with authentic flavors and familiar tastes, said Richard Ng. “It’s a new concept, and we hope it takes off,” said Ng, co-owner of Bo’s Kitchen at 108 E. 5th St. in the River…